Despite Humira's Challenges, AbbVie's Execution Makes It A Buy

Hailshadow Introduction The healthcare sector has always been fascinating to me. It combines innovative approaches that can achieve a significant premium for its products with essential products. Therefore, these companies tend to be more resilient to economic uncertainties. One such company is AbbVie (NYSE:ABBV), which I analyzed almost two years ago. I hold shares in the company in my dividend growth portfolio. The company is a leading pharmaceutical giant that had to deal with the loss of exclusivity ...